Phase 2b study of the novel vaccine Amb a 1 immunostimulatory DNA conjugate AIC in ragweed allergic adults

A. S. Nyak, W. Busse, P. Korenblat, G. Gross, D. Levitt (Normal, Madison, St. Louis, Dallas, Berkeley, United States Of America)

Source: Annual Congress 2006 - Established and experimental therapies for allergic asthma
Session: Established and experimental therapies for allergic asthma
Session type: Thematic Poster Session
Number: 2555
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. S. Nyak, W. Busse, P. Korenblat, G. Gross, D. Levitt (Normal, Madison, St. Louis, Dallas, Berkeley, United States Of America). Phase 2b study of the novel vaccine Amb a 1 immunostimulatory DNA conjugate AIC in ragweed allergic adults. Eur Respir J 2006; 28: Suppl. 50, 2555

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Evaluation of the immunogenicity and safety of a new formulation of omalizumab (solution for injection) in patients with allergic (IgE-mediated) asthma
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009


The effects of anti-IL-13 on allergen-induced responses; a Phase II study in subjects with mild atopic asthma - The allergen challenge as a model of allergic asthma for proof-of-concept studies
Source: Annual Congress 2008 - Clinical trial - The effects of an anti-IL-13 human monoclonal antibody, IMA-638, on allergen-induced airway responses in subjects with mild atopic asthma
Year: 2008


The influence of the allergen-specific immunotherapy (ASIT) against the backdrop of an immunomodulator in patients suffering from seasonal allergic rhinitis (SAR) on the level of cytokines, IgE and IgG.
Source: Virtual Congress 2020 – New insight into the pathogenesis of chronic lung diseases: asthma, COPD and others
Year: 2020


DNA vaccine encoding both PD-L1 and Der p 2 was more effective than DNA vaccine encoding only Der p 2 in suppressing airway inflammation in a murine model of allergic airway disease
Source: Annual Congress 2007 - Mouse models of allergic airway inflammation
Year: 2007


DNA vaccine encoding both FasL and Der p 2 was more effective than DNA vaccine encoding only Der p 2 in suppressing airway inflammation in a mouse model of asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 224s
Year: 2006

Efficiency of a DNA vaccine on allergic asthma
Source: Annual Congress 2012 - Asthma: mechanisms of airway inflammation
Year: 2012

Omalizumab (Xolair®) reduces exacerbations in adolescents more than in adults with allergic (IgE-mediated) asthma: a subgroup analysis of pooled clinical trials
Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Year: 2008


Efficacy and safety of the short term immunotherapy (SIT) in allergic rhinoconjunctivitis (AR)
Source: Eur Respir J 2005; 26: Suppl. 49, 134s
Year: 2005

A randomized double-blind study of specific immunotherapy (SIT) in patients with seasonal allergic rhinitis: effects on clinical and inflammatory markers
Source: Eur Respir J 2001; 18: Suppl. 33, 482s
Year: 2001

Evaluation and efficacy of allergen immunotherapy in asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 399s
Year: 2005

Relation between circulating allergen specific IgE, skin prick test reactivity and wheeze. Results from phase two of the international study of asthma and allergy in childhood (ISAAC)
Source: Annual Congress 2008 - Asthma epidemiology
Year: 2008

Allergen specific immunotherapy efficacy in children with pollen-food allergy syndrome and different IgE profiles to recombinant component-resolved allergens.
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017

Dermatophagoïdes Farinae 1 (Der f1) vaccine in a mice model of allergic asthma
Source: Annual Congress 2013 –Murine models of lung immunology
Year: 2013


Novel intradermal influenza vaccine: phase 3 data in targeted adult populations
Source: Annual Congress 2008 - Wider aspects of managing respiratory disease in primary care
Year: 2008


Allergen immunotherapy: therapeutic vaccines for allergic diseases
Source: ISSN=1025-448x, ISBN=1-904097-26-x, page=409
Year: 2003

Sublingual allergen specific immunotherapy in children with respiratory allergies – long lasting efficacy
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017

Co-administration of vaccination with DNA encoding T cell epitope on the Der p and BCG inhibited allergic responses in mice
Source: Eur Respir J 2003; 22: Suppl. 45, 483s
Year: 2003

Antibody response after varicella vaccination similar in children treated with budesonide inhalation suspension (BIS) or nonsteroidal conventional asthma therapy (NSCAT)
Source: Eur Respir J 2006; 28: Suppl. 50, 711s
Year: 2006

Effect of nasal polivalent bacterial lysate on the clinical course of seasonal allergic rhinitis in children - preliminary study.
Source: Virtual Congress 2020 – Novel mechanisms and management of paediatric asthma
Year: 2020